Photo by nci from unsplash
We thank Plus et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series… Click to show full abstract
We thank Plus et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ).1 2 Plus et al highlight a major point with respect to the consequences of the SARS-CoV2 outbreak on patients with SLE, in particular the difficulties that the latter have experienced in securing HCQ supplies for a licensed indication as a consequence of the off-label use of this drug to treat COVID-19 in the general population. Plus et al report that 70% of patients with SLE in Germany expressed concerns regarding the inability to receive their prescriptions for HCQ which was furthermore underscored by the observation that 46% also reported HCQ …
Journal Title: Annals of the Rheumatic Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!